Skip to content

Genomic epidemiology and resistance determinants of Pseudomonas aeruginosa in bronchiectasis across China: a multicentre study.

Sep 2026 · International Journal of Antimicrobial Agents · pp. 108010 · 0 citations · 37 references
Medicine

Abstract

Objectives

To characterise the genomic epidemiology and resistance determinants of bronchiectasis-associated Pseudomonas aeruginosa in a multicentre cohort.

Methods

We analysed 306 first non-duplicate P. aeruginosa isolates (2019-2021). Antimicrobial susceptibility was determined by broth microdilution and mucoid phenotype was recorded. Whole-genome sequencing was used for MLST, core-genome SNP phylogeny, resistance and virulence gene screening, and amino-acid variation in gyrA/gyrB/parC/parE, oprD, efflux regulators and mucoidy regulators (mucA, algU, mucB and mucD).

Results

Mucoid isolates comprised 68.6% of the collection. 201 sequence types indicated a polyclonal population without geographic or phenotype-specific clustering. Resistance was highest to levofloxacin (41.5%) and ciprofloxacin (39.2%), and lowest to amikacin (0.3%). Multidrug-resistant isolates accounted for 16.3%. Species-associated determinants were near-universal (blaPAO, aph(3')-IIb, fosA, catB7 and blaOXA-50), whereas acquired genes were uncommon. Among fluoroquinolone-resistant isolates, 97.0% carried amino-acid changes in at least one quinolone target gene, with canonical QRDR hotspots alongside additional variants such as gyrA (S912_E913del) and gyrB (H148N). In imipenem-resistant isolates, oprD variation was detected in 98.1% (52/53). Mucoid isolates were enriched for mucA variation (88.6% vs 57.3%). Virulence profiling revealed a largely conserved repertoire characterised by alginate regulation, quorum sensing and secreted toxins, with an exoS-predominant T3SS and broadly distributed T6SS components.

Conclusions

Bronchiectasis-associated P. aeruginosa constitutes a polyclonal, genetically heterogeneous population. Non-susceptibility predominantly reflects intrinsic and adaptive genomic mechanisms. Given the high fluoroquinolone resistance observed, treatment should be guided by local resistance patterns and isolate-specific susceptibility results.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.